The biotechnology company Outlook Therapeutics awaits the FDA's decision on its eye drug Lytenava on July 29, while on July 16, shareholders will vote on a crucial capital increase for its survival.
The biotechnology company Outlook Therapeutics faces a decisive July with two events that will determine its future. On July 29, the FDA (U.S. Food and Drug Administration) will decide whether to approve its drug Lytenava (ONS-5010), a formulation of bevacizumab for wet macular degeneration. If approval is granted, it would be the first time the agency authorises an ocular bevacizumab. However, prior to that, on July 16, shareholders must vote on a capital increase without which the company may not survive.
A fast-track review and a path full of obstacles
The application to the FDA has been classified as Class 1, which reduces the review time to 60 days. This step comes after a long process: in December 2025, the agency issued a rejection, but the biotechnology company's appeal succeeded by recognising that the efficacy data was sufficient. No additional clinical trials are required; only the details of labelling and manufacturing processes remain to be finalised.
Lytenava is already marketed in Germany, Austria, and the United Kingdom, and the company has begun preparations for its launch in the United States. Additionally, it plans to expand into more European markets throughout 2026, leveraging approvals from the European Commission and the UK agency MHRA. However, regulatory optimism clashes with financial reality.
The shadow of bankruptcy: capital increase on July 16
The management of Outlook Therapeutics has expressed “substantial doubts” about the company's ability to continue as a viable business. Current resources, including the $5 million raised in April through a private placement of 8.5 million shares at $0.5855 each with investor GMS Ventures, are insufficient to cover the needs for the next twelve months.
To alleviate this pressure, the board proposes to raise the number of authorised shares from 260 to 600 million and, simultaneously, to authorise a share consolidation in a range of between 1:10 and 1:50. This measure, which will be put to a vote on July 16, carries a potential significant dilution for current shareholders, a common risk in developing biotechnology companies. If the board gives the green light, the company would gain leeway to continue operating and prepare for the commercial launch. But if the 'no' prevails, the board warns of layoffs, programme cancellations, or, in the worst-case scenario, bankruptcy.
Extreme volatility in the stock market and analysts' stance
The stock price has reflected this duality with extreme volatility. On Friday, shares fell by 6.55% to $1.57, in a session that analysts interpret as profit-taking ahead of key events. Despite this setback, the monthly balance remains spectacular: a gain of 76.40%, and since January, the value has surged by 137.88%.
The stock is trading 77.86% above its 50-day moving average ($0.88) and 69.14% above its 200-day moving average ($0.93). Nevertheless, it is still 47% below the annual high of $2.97 reached in August 2025. The annualised implied volatility of 173.64% illustrates the nervousness surrounding the stock. The relative strength index (RSI) stands at 60.5, indicating that there are still no overbought conditions.
The investment bank BTIG downgraded its recommendation from
You may also like
